問卷

TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Rheumatology

Division of General Internal Medicine

更新時間:2023-09-19

陳嘉夆
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

38Cases

2022-12-01 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2026-01-01 - 2030-12-31

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-02-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2025-11-01 - 2027-10-11

Phase I

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-01-16 - 2028-10-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2022-12-01 - 2025-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-07-31 - 2026-04-30

Phase II/III

Completed
A Multicenter, Randomized, Double-blind, Controlled, Phase 2b/3 Study to Assess the Efficacy and Safety of ABP-671 in Participants With Gout
  • Condition/Disease

    Gout

  • Test Drug

    ABP-671

Participate Sites
4Sites

Recruiting3Sites

Study ended1Sites

2024-12-01 - 2030-03-19

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-09-01 - 2030-10-28

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2020-12-01 - 2025-12-31

Phase IV

Active
Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis: a 12 Month, Single-arm, Observational Study in Taiwan Population
  • Condition/Disease

    Lupus Nephritis

  • Test Drug

    Myfortic 180 mg、360 mg Gastro-Resistant Tablets

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

1 2 3 4